278 related articles for article (PubMed ID: 35217094)
1. Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series.
Martins M; Bridoux F; Goujon JM; Meuleman MS; Ribes D; Rondeau E; Guerry MJ; Delmas Y; Levy B; Ducloux D; Kandel-Aznar C; Le Fur A; Garrouste C; Provot F; Gibier JB; Thervet E; Bruneval P; Rabant M; Karras A; Dragon Durey MA; Fremeaux-Bacchi V; Chauvet S
Am J Kidney Dis; 2022 Sep; 80(3):341-352. PubMed ID: 35217094
[TBL] [Abstract][Full Text] [Related]
2. C3 Glomerulopathy With Concurrent Thrombotic Microangiopathy: Clinical and Immunological Features.
Chabannes M; Rabant M; El Sissy C; Dragon-Durey MA; Vieira Martins P; Meuleman MS; Karras A; Buob D; Bridoux F; Daugas E; Audard V; Caillard S; Olagne J; Kandel C; Ferlicot S; Philipponnet C; Crepin T; Thervet E; Ducloux D; Frémeaux-Bacchi V; Chauvet S
Am J Kidney Dis; 2023 Sep; 82(3):279-289. PubMed ID: 37061020
[TBL] [Abstract][Full Text] [Related]
3. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.
Che M; Moran SM; Smith RJ; Ren KYM; Smith GN; Shamseddin MK; Avila-Casado C; Garland JS
Kidney Int; 2024 May; 105(5):960-970. PubMed ID: 38408703
[TBL] [Abstract][Full Text] [Related]
4. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
[TBL] [Abstract][Full Text] [Related]
5. Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies.
Maisons V; Duval A; Mesnard L; Frimat M; Fakhouri F; Grangé S; Servais A; Cartery C; Fauchier L; Coppo P; Titeca-Beauport D; Fage N; Delmas Y; Quérard AH; Seret G; Bobot M; Le Quintrec M; Ville S; von Tokarski F; Chauvet S; Wynckel A; Martins M; Schurder J; Barbet C; Sautenet B; Gatault P; Caillard S; Vuiblet V; Halimi JM;
Kidney Int; 2024 May; 105(5):1100-1112. PubMed ID: 38431217
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathy associated with monoclonal gammopathy.
Ravindran A; Go RS; Fervenza FC; Sethi S
Kidney Int; 2017 Mar; 91(3):691-698. PubMed ID: 27998645
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
8. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F
Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
10. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
[TBL] [Abstract][Full Text] [Related]
11. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
Huerta A; Arjona E; Portoles J; Lopez-Sanchez P; Rabasco C; Espinosa M; Cavero T; Blasco M; Cao M; Manrique J; Cabello-Chavez V; Suñer M; Heras M; Fulladosa X; Belmar L; Sempere A; Peralta C; Castillo L; Arnau A; Praga M; Rodriguez de Cordoba S
Kidney Int; 2018 Feb; 93(2):450-459. PubMed ID: 28911789
[TBL] [Abstract][Full Text] [Related]
14. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
Kistler AD
Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
[TBL] [Abstract][Full Text] [Related]
15. Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study.
Laber DA; Patel PC; Logothetis CN; Patel AK; Jaglal M; Haider M; Visweshwar N; Rajasekaran-Rathnakumar G; Eatrides J
Eur J Haematol; 2024 Mar; 112(3):450-457. PubMed ID: 37984551
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.
Fakhouri F; Frémeaux-Bacchi V
Nat Rev Nephrol; 2021 Aug; 17(8):543-553. PubMed ID: 33953366
[TBL] [Abstract][Full Text] [Related]
17. Scleroderma Renal Crisis Associated With Microangiopathic Hemolytic Anemia in a Patient With Seronegative Scleroderma and Monoclonal Gammopathy.
Riley M; Der Mesropian P; Maheshwari A; Arslan ME; Visrodia P; Salman L; Peredo-Wende R; Foulke L; Hongalgi K
J Investig Med High Impact Case Rep; 2022; 10():23247096221074591. PubMed ID: 35152792
[TBL] [Abstract][Full Text] [Related]
18. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
Asif A; Nayer A; Haas CS
J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
[TBL] [Abstract][Full Text] [Related]
19. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
